Logo image
Sign in
Efficacy and Safety of Elbasvir/Grazoprevir for 8 or 12 Weeks in Participants with Hepatitis C Virus Genotype 4 Infection
Journal article   Peer reviewed

Efficacy and Safety of Elbasvir/Grazoprevir for 8 or 12 Weeks in Participants with Hepatitis C Virus Genotype 4 Infection

Tarik Asselah, Stanislas Pol, Christophe Hezode, Veronique Loustaud Ratti, Vincent Leroy, Si Nafa Si Ahmed, Violaine Ozenne, Jean-Pierre Bronowicki, Dominique Larrey, Albert Tran, …
Hepatology, Vol.68(1)
2018
url
Find in HALView

Metrics

1 Record Views

Details

Logo image